OBEZİTE: YENİ BİYOBELİRTEÇLER VE SEMAFORİN AİLESİ
Özet
Son yıllarda hem çocuklarda hem de yetişkinlerde küresel çapta artış gösteren obezite, ciddi bir halk sağlığı sorunu haline gelmiştir. Obezitenin patofizyolojisini anlamak, hastalıkların önlenmesi ve kişiselleştirilmiş tedavi stratejilerinin geliştirilmesi açısından büyük önem taşımaktadır. Glukoz-insülin homeostazında yer alan insülin, proinsülin, IGF-1 ve C-peptid gibi geleneksel biyobelirteçler, metabolik risklerin ve kardiyovasküler hastalıkların izlenmesinde kullanılmaktadır. Bunların yanı sıra adiponektin, omentin, apelin, leptin, resistin ve FABP4 gibi yağ dokusundan salgılanan adipokinler ile CRP gibi inflamasyon göstergeleri, insülin direnci ve metabolik bozukluklarla doğrudan ilişkilidir. Günümüzde omiks tabanlı yaklaşımlar ve yeni moleküller biyobelirteç araştırmalarına yeni bir boyut kazandırmıştır. Bu moleküllerden biri olan semaforin gen ailesi (özellikle Sınıf-3 semaforinler), hücresel sinyal iletimindeki rollerinin yanı sıra adipogenez, kahverengi yağ dokusu fonksiyonu, yağ dokusu inflamasyonu ve insülin direncinin düzenlenmesinde kritik görevler üstlenmektedir. Yapılan çalışmalar, Sema3A, Sema3C, Sema3E ve Sema3G gibi semaforin üyelerinin obezite ve metabolik bozukluklarda potansiyel biyobelirteç ve terapötik hedef olarak kullanılabileceğini göstermektedir.
Referanslar
Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13–27.
Pischon T. Use of obesity biomarkers in cardiovascular epidemiology. Dis Markers 2009;26:247– 63.
Kusters YH, Schalkwijk CG, Houben AJ, Kooi ME, Lindeboom L, Op ’t Roodt J, et al. Independent tissue contributors to obesity-associated insulin resistance. JCI Insight 2017;2.
Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol 2017;960:1– 17.
Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med 2017;23:804 –14.
Aleksandrova K, Drogan D, Boeing H, Jenab M, Bas Bueno-de Mesquita H, Jansen E, et al. Adiposity, mediating biomarkers and risk of colon cancer in the European prospective investigation into cancer and nutrition study. Int J Cancer 2014;134:612–21
Higashi Y, Quevedo HC, Tiwari S, Sukhanov S, Shai SY, Anwar A, Delafontaine P. Interaction between insulinlike growth factor-1 and atherosclerosis and vascular aging. Front Horm Res 2014;43:107–24.
Pramanik A, Ekberg K, Zhong Z, Shafqat J, Henriksson M, Jansson O, et al. C-peptide binding to human cell membranes: Importance of Glu27. Biochem Biophys Res Commun 2001;284:94 – 8.
Cardellini M, Farcomeni A, Ballanti M, Morelli M, Davato F, Cardolini I, et al. C-peptide: a predictor of cardiovascular mortality in subjects with established atherosclerotic disease. Diab Vasc Dis Res 2017;14:395–9.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270: 26746 –9.
Schondorf T, Maiworm A, Emmison N, Forst T, Pfutzner A. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab 2005;51:489 –94.
Aleksandrova K, Jenab M, Bueno-de-Mesquita HB, Fedirko V, Kaaks R, Lukanova A, et al. Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Epidemiolo 2014;29:261–75.
Komiya T, Tanigawa Y, Hirohashi S. Cloning of the novel gene intelectin, which is expressed in intestinal Paneth cells in mice. Biochem Biophys Res Commun 1998; 251:759 – 62.
Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophysica Acta 2005;1732: 96 –102.
Yang RZ, Lee MJ, Hu H, Pray J,WuHB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253– 61.
Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol. 2014 Jan;12:136 – 43.
Falcao-Pires I, Leite-Moreira AF. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol 2005;24:1263 76.
Castan-Laurell I, Dray C, Attane C, Duparc T, Knauf C, Valet P. Apelin, diabetes, and obesity. Endocrine 2011; 40:1–9.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372: 425–32.
Engin A. Diet-induced obesity and the mechanism of leptin resistance. Adv Exp Med Biol 2017;960:381–97.
Bluher S, Shah S, Mantzoros CS. Leptin deficiency: clinical implications and opportunities for therapeutic interventions. J Investig Med 2009;57:784 – 8.
Roujeau C, Jockers R,DamJ.Newpharmacological perspectives for the leptin receptor in the treatment of obesity. Front Endocrinol 2014;5:167.
Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004;304:1154 – 8.
Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300: 472– 6.
Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;1:e45.
Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489 –503.
Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking AP2. Endocrinology 2000;141:3388 –96.
Rhee EJ, Seo MH, Jeon WS, Won HK, Choi JH, Park SE, et al. The association of baseline adipocytokine levels with glycemic progression in nondiabetic Korean adults in 4 years of follow-up. Diabetes Res Clin Pract 2012;98:501–7.
Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis. Lancet 2010;375:132– 40.
Aleksandrova K, Mozaffarian D, Pischon, T. Addressing the perfect storm: biomarkers in obesity and pathophysiology of cardiometabolic risk. Clinical chemistry, 2018; 64(1), 142-153.
Worzfeld T, Offermanns S. Semaphorins and plexins as therapeutic targets. Nature reviews Drug discovery, 2014;13(8), 603-621.
Xia J, Worzfeld T. Semaphorins and plexins in kidney disease. Nephron, 2016;132(2), 93-100.
Lu Q, Zhu L. The Role of Semaphorins in Metabolic Disorders. International Journal of Molecular Sciences, 2020;21(16), 5641.
Liu, X.; Tan, N.; Zhou, Y.; Zhou, X.; Chen, H.; Wei, H.; Chen, J.; Xu, X.; Zhang, S.; Yang, G.; et al. Semaphorin 3A Shifts Adipose Mesenchymal Stem Cells towards Osteogenic Phenotype and Promotes Bone Regeneration In Vivo. Stem Cells Int. 2016, 2016, 2545214
Liu, M.; Xie, S.; Liu, W.; Li, J.; Li, C.; Huang, W.; Li, H.; Song, J.; Zhang, H. Mechanism of SEMA3G knockdown-mediated attenuation of high-fat diet-induced obesity. J. Endocrinol. 2020, 244, 223–236.
van der Klaauw AA, Croizier S, Mendes de Oliveira E, Stadler LKJ, Park S. et al. Human Semaphorin 3 Variants Link Melanocortin Circuit Development and Energy Balance. Cell 2019, 176, 729–742 e718.
Schmidt AM. Moore K.J. The Semaphorin 3E/PlexinD1 axis regulates macrophage inflammation in obesity. Cell Metab. 2013, 18, 461–462.
Mejhert N, Wilfling F, Esteve D, Galitzky J, et al. Semaphorin 3C is a novel adipokine linked to extracellular matrix composition. Diabetologia 2013, 56, 1792–1801
Sezgin G, Kar F, Uslu S. The effect of nutrition and exercise training on irisin and semaphorin-3E levels in obese patients. Archives of physiology and biochemistry, 2020; 1-10.